Anthony B. El-Khoueiry MD

Oncology•Los Angeles, CA

Gastrointestinal Cancer

Associate Professor, Medicine, USC School of Medicine Phase I Program Director

Join to View Full Profile

1441 Eastlake AveSte 8302ELos Angeles, CA 90089
Phone+1 323-865-3000
Fax+1 323-865-0061

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2003 - 2004
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2002 - 2003
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2001 - 2002
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1998 - 2001
Keck School of Medicine of the University of Southern CaliforniaClass of 1998

Certifications & Licensure

CA State Medical License 2000 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Start of enrollment: 2005 Oct 01
Completed
Phase 2
Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib Start of enrollment: 2008 Mar 01
Completed
Phase 1
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 2
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2011 Mar 03
Completed
Phase 1
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors Start of enrollment: 2011 Feb 01
Terminated
Phase 1
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Start of enrollment: 2012 Sep 06
Terminated
Phase 1
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
COMPLETED
PHASE2
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors Start of enrollment: 2012 Sep 01
Suspended
Phase 1
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Start of enrollment: 2013 Aug 23
Terminated
Phase 1
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors Start of enrollment: 2013 Nov 08
Completed
Phase 1
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol) Start of enrollment: 2013 Nov 01
Completed
Phase 1
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment Start of enrollment: 2014 Apr 01
Completed
Phase 1
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Start of enrollment: 2014 Jul 23
Terminated
Phase 2
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma Start of enrollment: 2015 Nov 01
Terminated
Phase 3
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 Start of enrollment: 2017 Feb 09
COMPLETED
PHASE1, PHASE2
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Start of enrollment: 2018 Feb 07
ACTIVE_NOT_RECRUITING
PHASE1
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Start of enrollment: 2018 Feb 20
Completed
Phase 1
FID-007 in Treating Participants With Advanced Solid Tumors Start of enrollment: 2018 May 25
Recruiting
Phase 1
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
ACTIVE_NOT_RECRUITING
PHASE3
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Start of enrollment: 2021 Jul 28
RECRUITING
A Study in Subjects With Advanced Solid Tumors Start of enrollment: 2019 Dec 10
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

EphB4-ephrin-B2 are targets in castration resistant prostate cancer.
Grace Xiuqing Li, Binyun Ma, Shaobing Zhang, Ren Liu, Imran N Siddiqi
British Journal of Cancer. 2025-05-01
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Ruth Plummer, Mikael H Sodergren, Rose Hodgson, Bríd M Ryan, Nina Raulf
Cell Reports. Medicine. 2025-04-15
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastat...
Breelyn A Wilky, Gary K Schwartz, Michael S Gordon, Anthony B El-Khoueiry, Andrea J Bullock
Journal of Clinical Oncology. 2025-04-10

Lectures

Analysis of OX40 agonist antibody (PF-04518600) in patients with hepatocellular carcinoma.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor re...
2019 ASCO Annual Meeting - 6/1/2019
A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Accelerated Approval of Nivolumab in HCC based on Phase I subgroup data. Continuous Evolution of a Phase I Trial Into An FDA Package
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Join now to see all

Press Mentions

Regorafenib plus Pembrolizumab Among Patients with Advanced Hepatocellular Carcinoma Previously Exposed to ImmunotherapyJuly 18th, 2024
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical OncologyMay 26th, 2023
Agenus (AGEN) Q1 2023 Earnings Call TranscriptMay 9th, 2023
Join now to see all